Assessing the reach of nicotine replacement therapy as a preventive public health measure

Chronic Diseases and Injuries in Canada

Volumn 33, Issue 1, 2012, Pages 19-28

  Bondy, S J ^a   Diemert, L M ^a   Victor, J C ^a,b   McDonald, P W ^a,c   Cohen, J E ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Evidence based medicine; Nicotine; Population surveillance; Smoking cessation

Indexed keywords

NICOTINE GUM; NON PRESCRIPTION DRUG;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO HEALTH; BEHAVIOR; CANADA; FEMALE; HEALTH BEHAVIOR; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; PUBLIC HEALTH; SMOKING; SMOKING CESSATION; STATISTICS; UTILIZATION REVIEW;

ADOLESCENT; ADULT; FEMALE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTENTION; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; ONTARIO; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PUBLIC HEALTH; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; YOUNG ADULT;

EID: 84871639050     PISSN: 02288699     EISSN: 14818523     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;1:CD000146. doi: 10.1002/14651858.CD000146.pub3.(2)
2. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;3:CD000146. doi: 10.1002/14651858.CD000146.pub3
3. Clinical Practice Guideline Treating Tobacco Use and Dependence Update Panel. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med. 2008;35(2):158-76.
4. World Health Organization. WHO Framework Convention on Tobacco Control. Geneva (CH): World Health Organization; 2003.
5. World Health Organization. WHO Framework Convention on Tobacco Control [Fifty-sixth World Health Assembly Resolution WHA56.1. Agenda item 13, 21 May 2003] Resolution WHA56.1. WHO Framework Convention on Tobacco Control. In: 56th World Health Assembly, Geneva, 19-34 May 2003 [Internet]. Geneva (CH): World Health Organization; 2008 [cited 2010 Jul 1]. Available from: http://apps.who.int/gb/archive/pdf_files/WHA56/ea56r1.pdf
6. World Health Organization. WHO Framework Convention on Tobacco Control: guidelines for implementation Article 5.3; Article 8; Articles 9 and 10; Article 11; Article 12; Article 13; Article 14 -2011 edition. Geneva: World Health Organization; 2011.
7. Pierce JP, Gilpin E. Impact of over-thecounter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288:1260-4.
8. Shiffman S, Gitchell J, Pinney JM, Burton SL, Kemper KE, Lara EA. Public health benefit of over-the-counter nicotine medications. Tob Control. 1997;6:306-10.
9. Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. Ann Rev Public Health. 2005;26:583-99.
10. Hyland A, Rezaishiraz H, Giovino G, Bauer JE, Michael Cummings K. Over-the-counter availability of nicotine replacement therapy and smoking cessation. Nicotine Tob Res. 2005;7(4):547-55.
11. Shiffman S, Sweeney CT. Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability? Health Policy. 2008;86:17-26.
12. Kotz D, Fidler J, West R. Factors associated with the use of aids to cessation in English smokers. Addiction. 2009;104(8):1403-10.
13. Vogt F, Hall S, Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies. Nicotine Tob Res. 2008;10(8):1405-13.
14. Ismailov RM, Leatherdale ST. Smoking cessation aids and strategies among former smokers in Canada. Addict Behav. 2010; 35(3):282-5.
15. Penz ED, Manns BJ, Hebert PC, Stanbrook MB. Governments, pay for smoking cessation. CMAJ. 2010;182(18):E810.
16. Smoke-Free ON Scientific Advisory Committee. Evidence to guide action: comprehensive tobacco control in Ontario. Toronto (ON): Ontario Agency for Health Protection and Promotion; 2010.
17. Schwartz R, O'Connor S, Minian N, Borland T, Babayan A, Ferrence R, et al. Evidence to inform smoking cessation policymaking in Ontario [Internet]. Toronto (ON): Ontario Tobacco Research Unit; 2009 [cited 2012 Jul 18]. Available from: http://www.otru.org/pdf/special/special_CAP_august2010.pdf
18. Jilcott S, Ammerman A, Sommers J, Glasgow R. Applying the RE-AIM framework to assess the public health impact of policy change. Ann Behav Med. 2007; 34(2):105.
19. Chapman S, MacKenzie R. The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med. 2010;7(2):e1000216.
20. Zawertailo L, Dragonetti R, Bondy SJ, Fictor JC, Selby PL. Reach and effectiveness of mailed nicotine replacement therapy for smokers: six-month outcomes in a naturalistic, exploratory study. Tob Control. 2012. doi: 10.1136/tobaccocontrol-2011-050303
21. Miller N, Frieden TR, Liu SY, Matte TD, Mostashari F, Deitcher DR, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. Lancet. 2005;365(9474):1849-54.
22. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update: A U.S. Public Health Service report. Am J Prev Med. 2008;35(2):158-76.
23. Etter JF, Burri M, Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a metaanalysis. Addiction. 2007;102(5):815-22.
24. Etter JF, Stapleton J. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control. 2006;15:280-5.
25. Shiffman S, Rolf CN, Hellebusch SJ, Gorsline J, Gorodetzky CW, Chiang Y-K, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 2002;97(5):505-16.
26. Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of abstinence: a metaanalysis. Addict Behav. 2008;33:1516-20.
27. West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the 'real world'? Findings from a prospective multinational cohort study. Thorax. 2007;62(11):998-1002.
28. Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of over-thecounter nicotine replacement. Tob Control. 2003;12:21-7.
29. Cummings KM, Hyland A, Fix B, Bauer U, Celestino P, Carlin-Menter S, et al. Free nicotine patch giveaway program 12-month follow-up of participants. Am J Prev Med. 2006;31(2):181-4.
30. Shiffman S, Gorsline J, Gorodetzky CW. Efficacy of over-the-counter nicotine patch. Nicotine Tob Res. 2002;4(4):477-83.
31. Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD, et al. Over-thecounter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am J Public Health. 1999; 89(11):1701-7.
32. Davidson M, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. Arch Fam Med. 1998;7(6):569-74.
33. Sonderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine patches in smoking cessation: a randomized trial among overthe-counter customers in Denmark. Am J Epidemiol. 1997;145(4):309-18.
34. Levy DE, Thorndike AN, Biener L, Rigotti NA. Use of nicotine replacement therapy to reduce or delay smoking but not to quit: prevalence and association with subsequent cessation efforts. Tob Control. 2007;16:384-9.
35. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338:b1024.
36. Hammond D, Reid JL, Driezen P, Cummings KM, Borland R, Fong GT, et al. Smokers' use of nicotine replacement therapy for reasons other than stopping smoking: findings from the ITC Four Country Survey. Addiction. 2008;103(10):1696-703.
37. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. J Clin Psychopharmacol. 2002;22:487-95.
38. Wang D, Connock M, Barton P, Fry-Smith A, Aveyard PMoore D. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technol Assess. 2008;12(2):1-135.
39. Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. Drug Alcohol Rev. 2008;27:529-47.
40. Temple NJ. Governments, pay for smoking cessation. CMAJ. 2010;182(16):1761-2.
41. Diemert L, Victor JC, Bondy SJ. Ontario Tobacco Survey Technical Report 1: Baseline Data [Internet]. Toronto (ON): Ontario Tobacco Research Unit; 2010 [updated 2010 Apr], Available from: http://www.otru.org/ots_doc.html
42. Diemert L, Victor JC, Bondy SJ. Ontario Tobacco Survey Technical Report 2: Six and Twelve Month Data [Internet]. Toronto (ON): Ontario Tobacco Research Unit; 2010 Apr [updated 2010 Apr]. Available at: http://www.otru.org/ots_doc.html
43. Bondy SJ, Victor JC, O'Connor S, McDonald PW, Diemert LM, Cohen JE. Predictive validity and measurement issues in documenting quit intentions in population surveillance studies. Nicotine Tob Res. 2010;12(1):43-52.
44. Etter JF, Perneger TV. A comparison of two measures of stage of change for smoking cessation. Addiction. 1999;94(12):1881-9.
45. Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy. Tob Control. 2005; 14:346-55.
46. Etter JF, Duc TV, Perneger TV. Validity of the Fagerstrom test for nicotine dependence and of the Heaviness of Smoking Index among relatively light smokers. Addiction. 1999;94(2):269-81.
47. Okoli CT, Richardson CG, Ratner PA, Johnson JL. Non-smoking youths 'perceived' addiction to tobacco is associated with their susceptibility to future smoking. Addict Behav. 2009;34(12):1010-6.
48. Du Plessis V, Beshiri R, Bollman RD, Clemenson H. Definitions of 'rural'. Agriculture and Rural Working Paper Series Working Paper No. 61 [Internet]. Ottawa (ON): Statistics Canada; 2002 [cited 2008 Dec 12]. [Statistics Canada, Catalogue No.: 21-601-MIE - No. 061]. Available at: http://www.statcan.gc.ca/pub/21-601-m/2002061/4224867-eng.pdf
49. StataCorp. Stata Statistical Software: Release 10 (SE). College Station, TX: StataCorp LP; 2007.
50. Ialomiteanu ARAdlaf EM, CAMH Monitor Technical Guide 2006. Toronto (ON): Centre for Addiction and Mental Health; 2007.
51. Health Canada. Microdata User Guide: Canadian Tobacco Use Monitoring Survey (CTUMS): Annual: February to December 2006. Report. Ottawa (ON): Health Canada; 2007.
52. Prochaska J, DiClemente C. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51:390-5.
53. Reid JL, Hammond D. Tobacco use in Canada: patterns and trends, 2011 ed. Waterloo (ON): Propel Centre for Population Health Impact, University of Waterloo; 2011.
54. Solberg LI, Boyle RG, Davidson G, Magnan S, Link Carlson C, Alesci NL. Aids to quitting tobacco use: how important are they outside controlled trials? Prev Med. 2001;33(1):53-8.
55. Gilpin EA, Messer K, Pierce JP. Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success? Nicotine Tob Res. 2006;8(5):661-9.
56. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34(2):102-11.
57. Centers for Disease Control and Prevention. Quitting smoking among adults- United States, 2001-2010. MMWR. 2011; 60:1513-9.
58. Hughes JR, Marcy TW, Naud S. Interest in treatments to stop smoking. J Subst Abuse Treat. 2009;36(1):18-24.
59. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Individual differences in adoption of treatment for smoking cessation: demographic and smoking history characteristics. Drug Alcohol Depend. 2008;93(1- 2):121-31.
60. Selby P, Zawertailo L, Dragonetti R. The STOP Study, Eighth Interim Progress Report to the Ministry of Health Promotion. Toronto (ON): Centre for Addiction and Mental Health; 2008.
61. Alberg AJ, Patnaik JL, May JW, Hoffman SC, Gitchelle J, Comstock GW, et al. Nicotine replacement therapy use among a cohort of smokers. J Addict Dis. 2005; 24(1):101-13.
62. Paul CL, Walsh RA, Girgis A. Nicotine replacement therapy products over the counter: real-life use in the Australian community. Aust N Z J Public Health. 2003;27(5):491-5.
63. Al-Delaimy WK, Gilpin EA, Pierce JP. When California smokers use nicotine replacement therapy, most are trying to quit smoking. Tob Control. 2005;14(5): 359-60.
64. Peters EN, Hughes JR. The day-to-day process of stopping or reducing smoking: a prospective study of self-changers. Nicotine Tob Res. 2009;11(9):1083-92.
65. Department of Health and Ageing. Smoking cessation guidelines for Australian general practice: practice handbook. Canberra (AU): Department of Health and Ageing; 2004.
66. Shiffman S, Hughes JR, Di Marino ME, Sweeney CT. Patterns of over-the-counter nicotine gum use: persistent use and concurrent smoking. Addiction. 2003;98(12): 1747-53.
67. Shiffman S, Hughes JR, Pillitteri JL, Burton SL. Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample. Tob Control. 2003;12(3):310-6.
68. West R Sohal T. 'Catastrophic' pathways to smoking cessation: findings from national survey. BMJ. 2006;332(7539): 458-60.
69. Walsh RA. The Cochrane review on nicotine replacement therapy: incorrect or uncertain classifications of additional support levels. Tob Control. 2007;16(3): 215-6; author reply 6.
70. Bansal MA, Cummings KM, Hyland A, Giovino GA. Stop-smoking medications: who uses them, who misuses them, and who is misinformed about them? Nicotine Tob Res. 2004;6(Suppl 3):S303-10.
71. Mooney ME, Leventhal AM, Hatsukami DK. Attitudes and knowledge about nicotine and nicotine replacement therapy. Nicotine Tob Res. 2006;8:435-46.
72. Shiffman S, Ferguson SG, Rohay J, Gitchell JG. Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction. 2008;103(8): 1371-8.
73. Raw M, McNeill A, West R, Arnott D, Armstrong M. Nicotine Replacement Therapy. Guidance for health professionals on changes in the licensing arrangements for nicotine replacement therapy [Internet]. London (UK): Action on Smoking and Health (ASH);2005 [cited 2012 Jul 18]. Available from: http://www.ash.org.uk/files/documents/ASH_445.pdf